15-PGDH Inhibition Promotes Cartilage Regeneration in OA

Key Takeaways

• Increased 15-PGDH expression was observed in aged or injured mouse cartilage, and systemic or local inhibition was associated with cartilage regeneration and less OA-associated pain in mice.
• The regenerated tissue was described as hyaline articular cartilage rather than fibrocartilage, supported by collagen II and specific proteoglycan synthesis.
• Inhibition was associated with fewer hypertrophic-like and fibrogenic chondrocytes, more extracellular matrix–synthesizing articular chondrocytes, and similar gene-expression changes in human OA explants, with regeneration attributed to changes in preexisting chondrocytes rather than stem or progenitor cell proliferation.

Osteoarthritis, which afflicts mobility in one out of five adults, still has limited restorative treatment options. In a recent abstract, researchers described mouse osteoarthritis models in which short-term systemic or local inhibition of 15-hydroxy prostaglandin dehydrogenase (15-PGDH) with a small-molecule inhibitor was associated with regeneration of articular cartilage and reduced osteoarthritis-associated pain. The target, 15-PGDH, was presented as a prostaglandin-degrading enzyme linked to shifts in chondrocyte state and gene expression. The evidence summarized here is limited to mice and human osteoarthritis patient-derived cartilage explants, not treated patients.

The reported experimental settings included aged mice with osteoarthritis, young adult mice with posttraumatic osteoarthritis after ACL injury, and human cartilage explants from osteoarthritis patients undergoing knee replacement. Across the mouse settings, 15-PGDH expression was reported to be increased in articular cartilage from aged or injured mice, positioning the enzyme as the intervention target. Single-cell RNA-seq, multiplexed immunofluorescence imaging, and CODEX spatial proteomics were used to identify major chondrocyte subpopulations. Together, those analyses linked 15-PGDH inhibition to a shift in the balance of cartilage-cell states.

Within those models, pain was diminished in three well-established assays, and the regenerated tissue was characterized as hyaline articular cartilage rather than fibrocartilage. That description was supported by collagen II and specific proteoglycan synthesis, alongside a cartilage-cell pattern marked by fewer hypertrophic-like and fibrogenic chondrocytes and more extracellular matrix–synthesizing articular chondrocytes. Taken together, the structural, behavioral, and cell-state findings were presented as part of the same regenerative phenotype in aged and injured mouse joints. The reported net effect was a shift toward matrix-producing articular chondrocytes.

According to the authors, the regenerative response appeared to occur through gene-expression changes in preexisting chondrocytes rather than stem or progenitor cell proliferation, and similar gene-expression changes were observed in human OA explants. They also summarized decreased inflammation in human osteoarthritis explants in association with the inhibitor, a finding confined to explant data rather than patient treatment. Based on this, 15-PGDH inhibition was described as a potential disease-modifying and regenerative approach for osteoarthritis, with the evidence remaining preclinical and explant-based.